Shots: The study involves assessing of Praluent (75mg & 150mg, q2w) vs PBO in patients with MACE events and experienced ACS between 1 to 12 mos. in 18,924 patients for duration of 2.8 years The results included 29% reduction in rates of mortality with LDL-C level 100 mg/dL& reduction in cardiovascular events, with no new […]Read More
